NRG-HN014 is a clinical study that will be testing if adding the immunotherapy drug called “Cemiplimab” (REGN2810) prior to surgery can extend the length of time without your cancer returning for people with advanced skin cancer. Typically, patients with this type of cancer are treated with surgery first and, depending the results, may require radiation after surgery. For patients who get the usual approach, about 75 out of 100 are free of cancer after 2 years. Researchers want to know if the approach of surgery with the drug cemiplimab is better, worse, or the same as the usual treatment for people with advanced skin cancer.
More information about this particular study is located on ClinicalTrials.gov
Are you interested in joining the study?
Find a participating location
Below, you can find FAQs about clinical research and this particular clinical trial.
Doctors and researchers conduct a clinical study, also called a “clinical trial,” to find better ways to prevent, diagnose, or treat an illness. NRG Oncology is supported by the National Cancer Institute (NCI) and runs clinical studies specifically for patients with cancer or to prevent cancer. Most clinical studies test something we know against something we don’t know. In all situations, these studies are strictly evaluated before they are allowed to be offered to any patient. The study is designed to answer the question that we do not know the answer to, so that current and future patients may have better treatments or information than what we currently have. There are different types of clinical studies that might be available for patients. For more information see “Types of Clinical Trials” and “Phases of Clinical Trials”.
Patients who volunteer to take part in a clinical study are followed closely by their health care professionals and members of the research team. For more information see “Research Team Members”.
At NRG Oncology, we focus on conducting clinical studies aimed to improve current cancer care practices and the lives of cancer patients. NRG Oncology partners with more than 1,300 member sites world-wide to research ways to improve treatment standards in the cancer community. Our organization is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trial's Network.